Clinical Trials Logo

Clinical Trial Summary

Chemotherapy or target therapy-induced hand-foot syndrome in cancer patients affects the quality of life. At present, there is no better treatment for this side effect of chemotherapy or target therapy. In severe cases, it is necessary to reduce the dose of chemotherapy or target therapy, which may affect the progress and effect of chemotherapy. In recent years, acupuncture has been widely used for many side effects of chemotherapy, such as numbness of hands and feet, gastrointestinal discomfort, and dizziness. There have been many studies have proved to be effective, but quite few studies explored the acupuncture treatment improves the hand-foot syndrome caused by chemotherapy or target therapy in cancer patients. Therefore, the investigators expect to evaluate the efficacy of acupuncture, and applying acupuncture or laser acupuncture to improve hand-foot syndrome caused by chemotherapy or target therapy in cancer patients in the future.


Clinical Trial Description

The investigators design a single-center, sham-controlled, assessor- and subject- blind, randomized clinical trial. 60 subjects will be equally and randomly divided into an acupuncture group, laser acupuncture, and sham-laser acupuncture groups in the 6-week trial. Each subject receives acupuncture, laser acupuncture, or sham-laser acupuncture three times a week for three consecutive weeks depending on their group, with a total of 9 times interventions. Outcome measures include Common adverse events evaluation standard version 5.0 (CTCAE) and Visual Analogue Scale (VAS), Dermatology Life Quality Index (DLQI) and assessment of cancer patients' quality of life questionnaire (EORTC QLQ-C30). ANSWatch and Thermal Image Camera are also used to assess those subjects. Those outcome measures will be conducted at baseline, the 3rd and the 6th week after the interventions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05949307
Study type Interventional
Source China Medical University Hospital
Contact
Status Not yet recruiting
Phase N/A
Start date August 1, 2023
Completion date March 29, 2024

See also
  Status Clinical Trial Phase
Completed NCT04592731 - Acetylated Natural Nucleotides in Treating Hand-foot Syndrome N/A
Completed NCT05755646 - Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial N/A
Completed NCT00446147 - Study of Pyridoxine for Hand-Foot Syndrome Phase 3
Completed NCT01609166 - Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome Phase 2
Terminated NCT03173365 - The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients Phase 2
Recruiting NCT04979078 - Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction N/A
Recruiting NCT05165069 - The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome Phase 3
Recruiting NCT05348278 - Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome Phase 2/Phase 3
Recruiting NCT04833998 - Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine Phase 2